Pimecrolimus is a topical calcineurin inhibitor currently approved for second-line use in the management of mild-to-moderate atopic dermatitis in patients age 2 years and older. Given the safety profile and nonsteroidal mechanism of pimecrolimus, there has been significant interest in its use in the treatment of a variety of dermatological conditions. This article reviews research that has been published on the off-label uses of topical pimecrolimus, with a focus on published RCTs. Convincing evidence exists supporting pimecrolimus’ efficacy in oral lichen planus and seborrheic dermatitis. For other conditions studied to date, pimecrolimus may prove to be a useful treatment alternative when conventional agents fail. Adverse events seen with its off-label use were typically application site reactions, the most common being a transient burning sensation. In summary, pimecrolimus appears to be an effective agent in the treatment of multiple dermatological conditions and may be worth considering as a pharmacologic alternative in several conditions when first-line treatment fails, or for areas that are more susceptible to the adverse effects of topical corticosteroids.
GrassbergerMSteinhoffMSchneiderDLugerTA.Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004 Dec;13(12):721-730. doi:10.1111/j.0906-6705.2004.00269.x
2.
GutfreundKBieniasWSzewczykAKaszubaA.Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165-169. doi:10.5114/pdia.2013.35619
3.
PappKABreuerKMeurerMet al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52(2):247-253. doi:10.1016/j.jaad.2004.08.046
4.
AshcroftDMChenLCGarsideRSteinKWilliamsHC.Topical pimecrolimus for eczema. Cochrane Database Syst Rev. 2007;(4):CD005500. doi:10.1002/14651858.CD005500.pub2
5.
GribetzCLingMLebwohlMet al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738. doi:10.1016/j.jaad.2004.06.010
6.
KreuterASommerAHyunJet al. 1% Pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol. 2006;142(9):1138-1143. doi:10.1001/archderm.142.9.1138
7.
SwiftJCReesTDPlemonsJMHallmonWWWrightJC.The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol. 2005;76(4):627-635. doi:10.1902/jop.2005.76.4.627
8.
McCaugheyCMachanMBennettRZoneJJHullCM.Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol Venereol. 2011;25(9):1061-1067. doi:10.1111/j.1468-3083.2010.03923.x
PasseronTLacourJPFontasEOrtonneJP.Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol. 2007;143(4):472-476. doi:10.1001/archderm.143.4.472
11.
GorouhiFSolhpourABeitollahiJMet al. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. J Am Acad Dermatol. 2007;57(5):806-813. doi:10.1016/j.jaad.2007.06.022
12.
EzzattOMHelmyIM.Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial. Clin Oral Investig. 2019;23(2):947-956. doi:10.1007/s00784-018-2519-6
13.
ArduinoPGCarboneMDella FerreraFet al. Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study. J Eur Acad Dermatol Venereol. 2014;28(4):475-482. doi:10.1111/jdv.12128
14.
VohraSSingalASharmaSB.Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial. Int J Dermatol. 2016;55(1):101-105. doi:10.1111/ijd.12887
15.
EsfandiarpourIEkhlasiAFarajzadehSShamsadiniS.The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20(1):14-18. doi:10.1080/09546630802155057
16.
DawidMVeensaluMGrassbergerMWolffK.Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006;4(11):942-946. doi:10.1111/j.1610-0387.2006.06124.x
17.
StincoGPiccirilloFForcioneMValentFPatroneP.An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol. 2009;19(6):588-593. doi:10.1684/ejd.2009.0779
18.
WeissenbacherSMerklJHildebrandtBet al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156(4):728-732. doi:10.1111/j.1365-2133.2006.07669.x
19.
KocaRAltinyazarHCAnkaraliHMuhtarSTekinNSCinarS.A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol. 2010;35(3):251-256. doi:10.1111/j.1365-2230.2009.03427.x
20.
WarshawEMWohlhuterRJLiuAet al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57(2):257-264. doi:10.1016/j.jaad.2006.11.007
21.
KocEArcaEKoseOAkarA.An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009;20(1):4-9. doi:10.1080/09546630802286993
22.
FiroozASolhpourAGorouhiFet al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142(8):1066-1067. doi:10.1001/archderm.142.8.1066
23.
RigopoulosDIoannidesDKalogeromitrosDGregoriouSKatsambasA.Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151(5):1071-1075. doi:10.1111/j.1365-2133.2004.06208.x
24.
CicekDKandiBBakarSTurgutD.Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009;20(6):344-349. doi:10.3109/09546630802687349
25.
BelsitoDVFowlerJFJrMarksJGJret al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004;73(1):31-38.
26.
HordinskyMFleischerARiversJKPoulinYBelsitoDHultschT.Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial. Dermatology. 2010;221(1):71-77. doi:10.1159/000297524
27.
SchwarzTKreiselmaierIBieberTet al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008;59(1):34-40. doi:10.1016/j.jaad.2008.03.043
28.
OppelTPavicicTKamannSBräutigamMWollenbergA.Pimecrolimus cream (1%) efficacy in perioral dermatitis – results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007;21(9):1175-1180. doi:10.1111/j.1468-3083.2007.02191.x
29.
BhardwajSSJaimesJPLiuAWarshawEM.A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis. Dermatitis. 2007;18(1):26-31.
30.
AmrolDKeitelDHagamanDMurrayJ.Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol. 2003;91(6):563-566. doi:10.1016/S1081-1206(10)61535-9
DraelosZD.Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24(4):985-994. doi:10.1185/030079908X280419
33.
LavanyaNJayanthiPRaoUKRanganathanK.Oral lichen planus: an update on pathogenesis and treatment. J Oral Maxillofac Pathol. 2011;15(2):127-132. doi:10.4103/0973-029X.84474
34.
CribierBFrancesCChosidowO.Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol. 1998;134(12):1521-1530.
35.
RappersbergerKKomarMRichterLet al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 2002 Oct 1;119(4):876–87. doi:10.1046/j.1523-1747.2002.00694.x
36.
MangaPElbulukNOrlowSJ.Recent advances in understanding vitiligo. F1000Res. 2016;5.
KostnerLAnzengruberFGuillodCRecherMSchmid-GrendelmeierPNavariniAA.Allergic contact dermatitis. Immunol Allergy Clin North Am. 2017;37(1):141-152. doi:10.1016/j.iac.2016.08.014
44.
BarikbinBGivradSYousefiMEskandariF.Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34(7):776-780. doi:10.1111/j.1365-2230.2008.03138.x
45.
SiepmannDLottsTBlomeCet al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology. 2013;227(4):353-360. doi:10.1159/000355671
46.
GoldsteinATCreaseyAPfauRPhillipsDBurrowsLJ.A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64(6):e99-e104. doi:10.1016/j.jaad.2010.06.011
47.
UcakHKandiBCicekDHalisdemirNDertlıoğluSB.The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatolog Treat. 2012;23(6):410-420. doi:10.3109/09546634.2011.590788
48.
Chams-DavatchiCBarikbinBShahramFet al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010;13(3):253-258. doi:10.1111/j.1756-185X.2010.01531.x
49.
IrajiFAsilianASiadatAH.Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol. 2010;9(6):684-686.
ChiaBKYTeyHL.Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis. 2015;26(3):122-132. doi:10.1097/DER.0000000000000118
52.
CastellsagueJKuiperJGPottegårdAet al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study). Clin Epidemiol. 2018;10:299-310. doi:10.2147/CLEP.S146442
53.
LugerTBoguniewiczMCarrWet al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306-315. doi:10.1111/pai.12331
54.
MargolisDJAbuabaraKHoffstadOJWanJRaimondoDBilkerWB.Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015;151(6):594-599. doi:10.1001/jamadermatol.2014.4305
